CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES...Titan Pharmaceuticals Inc • November 13th, 2013 • Biological products, (no disgnostic substances)
Reference is made to the License Agreement (the “Original License”) dated December 14, 2012 between Titan Pharmaceuticals, Inc. (“Titan”) and Braeburn Pharmaceuticals Sprl (“Braeburn”), as amended by written agreement dated May 28, 2013 (the “First Amendment”) and written agreement dated July 3, 2013 (the “Second Amendment”) (together, the Original License, the First Amendment and the Second Amendment comprise the “Agreement”). Contemporaneously with the execution and delivery of this letter agreement, Titan and Braeburn are entering into a Stock Purchase Agreement (the “SPA”) with respect to the purchase by Braeburn from Titan of shares of Titan common stock.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 13th, 2013 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of November 12, 2013, by and among Titan Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 400 Oyster Point Blvd., Suite 505, South San Francisco, California 94080 (the “Company”), and the investor identified on the signature pages hereto (the “Investor”).
